Clinical Trials Using Dacomitinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Dacomitinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Dacomitinib in Treating Patients with Metastatic EGFR Mutant Lung Cancers with Disease Progression on Osimertinib
This pilot early phase I trial studies how well dacomitinib works in treating patients EGFR mutant lung cancers that has spread to other places in the body and has progressed after treatment with osimertinib. Dacomitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 6 locations
Dacomitinib and Osimertinib in Treating Patients with Metastatic EGFR Mutant Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of dacomitinib and osimertinib in treating patients with EGFR mutant non-small cell lung cancer that has spread to other places in the body. Dacomitinib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Memorial Sloan Kettering Cancer Center, New York, New York
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K / mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
Location: See Clinical Trials.gov